Mark Ratner Joins AAM to Lead Government Relations

Brings over twenty years of legislative and policy experience

WASHINGTON (July 7, 2025) — The Association for Accessible Medicines today welcomes Mark Ratner as Senior Vice President of Government Affairs. Ratner served for over twenty years in key policy positions on Capitol Hill.

“We are thrilled to welcome Mark to the AAM and Biosimilars Council team,” said John Murphy III, President and CEO of AAM. “He has already hit the ground running and will be a key leader in our advocacy efforts to bring about common-sense reforms to ensure sustainable and affordable generics and biosimilar medicines for patients across the country.”

Ratner most recently served as chief of staff for U.S. Representative Bryan Steil of Wisconsin. Previously he was a senior advisor on the Senate Health Committee as was as legislative director and deputy chief of staff for U.S. Representative Fred Upton of Michigan. He was worked for the House Energy and Commerce Committee and for U.S. Representative Joe Schwarz of Michigan.

“I am excited to join the Association for Accessible Medicines and help advance its mission to increase patient access to affordable, life-saving generic and biosimilar medicines,” said Ratner. “I look forward to working with policymakers and stakeholders to support a competitive, sustainable healthcare system that delivers real value to patients across the country.”

He will lead the government relations team which includes federal relations, state relations, as well as advocacy and alliances.

For media inquiries, contact the Communications department at media@accessiblemeds.org.

About AAM

The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.